MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- MERCK LIMITED (pharmaceuticals)
- Latest 8 Quarter Result
Procter & Gamble Health Quarterly Results (EMER)
Here are the latest quarterly results of Procter & Gamble Health. For more details, see the Procter & Gamble Health financial fact sheet and Procter & Gamble Health share price and chart. For a sector overview, read our pharmaceuticals sector report.
Procter & Gamble Health Quarterly Results
| No. of Mths Qtr. Ending |
3
Sep-17 |
3
Dec-17 |
3
Mar-18 |
3
Jun-18 |
3
Sep-18 |
3
Dec-18 |
3
Mar-19 |
3
Jun-19 |
8-Qtr Chart Click to enlarge |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 3,127 | 3,041 | 3,012 | 2,203 | 2,261 | 2,044 | 2,310 | 2,336 | |
| Other income | Rs m | 65 | 54 | 55 | 58 | 61 | 72 | 177 | 175 | |
| Turnover | Rs m | 3,192 | 3,095 | 3,067 | 2,261 | 2,322 | 2,116 | 2,487 | 2,511 | |
| Expenses | Rs m | 2,561 | 2,734 | 2,595 | 1,695 | 1,680 | 1,890 | 1,809 | 1,791 | |
| Gross profit | Rs m | 566 | 307 | 482 | 508 | 582 | 153 | 501 | 545 | |
| Depreciation | Rs m | 67 | 71 | 86 | 49 | 43 | 46 | 43 | 45 | |
| Interest | Rs m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Profit before tax | Rs m | 564 | 291 | 451 | 517 | 599 | 179 | 635 | 675 | |
| Tax | Rs m | 248 | 188 | 224 | 189 | 188 | 44 | 228 | 234 | |
| Profit after tax | Rs m | 317 | 103 | 227 | 328 | 411 | 135 | 407 | 441 | |
| Gross profit margin | % | 18.1 | 10.1 | 16.0 | 23.1 | 25.7 | 7.5 | 21.7 | 23.3 | |
| Effective tax rate | % | 43.9 | 64.6 | 49.7 | 36.5 | 31.4 | 24.6 | 35.9 | 34.7 | |
| Net profit margin | % | 10.1 | 3.4 | 7.5 | 14.9 | 18.2 | 6.6 | 17.6 | 18.9 | |
| Diluted EPS | Rs | 19.1 | 6.2 | 13.7 | 19.8 | 24.8 | 8.1 | 24.5 | 26.6 | |
| Diluted EPS (TTM) | Rs | 51.1 | 46.3 | 51.1 | 58.7 | 64.4 | 66.3 | 77.2 | 84.0 | |
 Subscriber Feature |
||||||||||
Interim results exclude extraordinary / exceptional items
Read: Procter & Gamble Health 1QFY20 Result Performance Review
More Pharmaceuticals Company Quarterly Results: SANOFI INDIA PANACEA BIOTECH GLENMARK PHARMA SUVEN LIFESCIENCES NOVARTIS
Compare PROCTER & GAMBLE HEALTH With: SANOFI INDIA PANACEA BIOTECH GLENMARK PHARMA SUVEN LIFESCIENCES NOVARTIS
Compare PROCTER & GAMBLE HEALTH With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Tanks 642 Points; Automobile and Realty Stocks Plunge(Closing)
Indian share markets fell sharply today amid fears of rising crude oil prices and weakness in the rupee rattled investor sentiment.
Views on news
PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)
Aug 13, 2019 | Updated on Aug 13, 2019For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.
PROCTER & GAMBLE HEALTH 2017-18 Annual Report Analysis (Annual Result Update)
Aug 8, 2019 | Updated on Aug 8, 2019Here's an analysis of the annual report of PROCTER & GAMBLE HEALTH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PROCTER & GAMBLE HEALTH. Also includes updates on the valuation of PROCTER & GAMBLE HEALTH.
MERCK Announces Quarterly Results (4QFY19); Net Profit Up 79.2% (Quarterly Result Update)
May 13, 2019 | Updated on May 13, 2019For the quarter ended March 2019, MERCK has posted a net profit of Rs 407 m (up 79.2% YoY). Sales on the other hand came in at Rs 2 bn (down 23.3% YoY). Read on for a complete analysis of MERCK's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
More Views on NewsMost Popular
Buying these Eight Stocks is Like Owning Your Own Business (Profit Hunter)
Sep 5, 2019Everyone dreams of owning a business. Here is your chance.
7 Stocks to Buy in the Market Today (The 5 Minute Wrapup)
Sep 5, 2019The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?
Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside (The 5 Minute Wrapup)
Sep 4, 2019Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.
Buy these 7 Stocks if You Believe in India (The 5 Minute Wrapup)
Sep 12, 2019News headlines predict gloom and doom for India these days. You should ignore them.
A Recession Proof Stock You Can Bet On (Profit Hunter)
Sep 10, 2019Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.
More|
| |
PROCTER & GAMBLE HEALTH SHARE PRICE
Sep 17, 2019 (Close)
TRACK PROCTER & GAMBLE HEALTH
- Track your investment in PROCTER & GAMBLE HEALTH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON PROCTER & GAMBLE HEALTH
PROCTER & GAMBLE HEALTH - MYLAN COMPARISON
COMPARE PROCTER & GAMBLE HEALTH WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.